Investor Centre

Pharmaxis hosted an investor research briefing on 20th November 2018 featuring presentations by a Boehringer Ingelheim global project manager and a research leader from the Garvan Institute of Medical Research. The event provided an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program.

Pharmaxis CEO Gary Phillips, Board member Dr Kathleen Metters and Head of Drug Discovery Wolfgang Jarolimek provided commercial and scientific perspectives.

Watch:

• Full briefing
• Welcome & Introduction - Gary Phillips (Chief Executive Officer Pharmaxis Ltd)
• Pharmaxis Science: A Board Perspective - Dr Kathleen Metters (non executive director Pharmaxis Ltd)
• Boehringer Ingelheim development program for BI 1467335 - Thomas Jensen (Project Manager IPM Cardiometabolic/CNS, Boehringer Ingelheim GmbHand) Dr Petra Moroni-Zentgraf (Medical Director, Boehringer Ingelheim Pty Ltd)
• Pharmaxis LOXL2 inhibitor program targeting fibrotic diseases of the liver, lung, heart & kidney
• Competitive profile - Dr Wolfgang Jarolimek (Head of Drug Discovery, Pharmaxis Ltd)
• Commercialisation plans - Gary Phillips (CEO Pharmaxis Ltd)
• Pharmaxis (oral) LOX program – targeting severe fibrotic conditions
• Pharmaxis LOX program - Dr Wolfgang Jarolimek (Head of Drug Discovery, Pharmaxis Ltd)
• Fibrosis, LOX & cancer – Dr Thomas R. Cox (Group Leader, Matrix and Metastasis, Cancer Division, Garvan Institute of Medical Research)
• Pharmaxis business strategy - Gary Phillips (CEO Pharmaxis Ltd)

   

 Recordings will be available until November 2019.

Dr Kathleen Metters is a global pharmaceutical industry executive with more than 25 years’ experience and, since June 2017, has served on the Pharmaxis Board. Dr Metters visited Sydney in May 2018 for a Pharmaxis Scientific Advisory Board meeting and the annual Pharmaxis Board strategic review.

Watch the interview here

Pharmaxis chief executive Gary Phillips speaks to Proactive Investors about the pharmaceutical research company’s business model and value drivers, and provides some context about the sector, which is seeing a lot of headline-grabbing merger and acquisition activity.Pharmaxis CEO Gary Phillips discusses the Company’s drug discovery team. (Watch the video here)